249 related articles for article (PubMed ID: 21179472)
1. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells.
Brazelle W; Kreahling JM; Gemmer J; Ma Y; Cress WD; Haura E; Altiok S
PLoS One; 2010 Dec; 5(12):e14335. PubMed ID: 21179472
[TBL] [Abstract][Full Text] [Related]
2. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
Wang G; Edwards H; Caldwell JT; Buck SA; Qing WY; Taub JW; Ge Y; Wang Z
PLoS One; 2013; 8(9):e76662. PubMed ID: 24098799
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
Zhao J; Xie C; Edwards H; Wang G; Taub JW; Ge Y
Oncotarget; 2017 Jan; 8(4):6319-6329. PubMed ID: 28030834
[TBL] [Abstract][Full Text] [Related]
4. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe.
Cornago M; Garcia-Alberich C; Blasco-Angulo N; Vall-Llaura N; Nager M; Herreros J; Comella JX; Sanchis D; Llovera M
Cell Death Dis; 2014 Oct; 5(10):e1435. PubMed ID: 25275596
[TBL] [Abstract][Full Text] [Related]
6. Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors.
Lee JH; Choy ML; Ngo L; Venta-Perez G; Marks PA
Proc Natl Acad Sci U S A; 2011 Dec; 108(49):19629-34. PubMed ID: 22106282
[TBL] [Abstract][Full Text] [Related]
7. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation.
Chuang MJ; Wu ST; Tang SH; Lai XM; Lai HC; Hsu KH; Sun KH; Sun GH; Chang SY; Yu DS; Hsiao PW; Huang SM; Cha TL
PLoS One; 2013; 8(9):e73401. PubMed ID: 24023871
[TBL] [Abstract][Full Text] [Related]
8. Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.
Qi W; Zhang W; Edwards H; Chu R; Madlambayan GJ; Taub JW; Wang Z; Wang Y; Li C; Lin H; Ge Y
Cancer Biol Ther; 2015; 16(12):1784-93. PubMed ID: 26529495
[TBL] [Abstract][Full Text] [Related]
9. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S
Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
11. Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells.
Pettazzoni P; Pizzimenti S; Toaldo C; Sotomayor P; Tagliavacca L; Liu S; Wang D; Minelli R; Ellis L; Atadja P; Ciamporcero E; Dianzani MU; Barrera G; Pili R
Free Radic Biol Med; 2011 Jan; 50(2):313-22. PubMed ID: 21078383
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.
Seo SK; Jin HO; Woo SH; Kim YS; An S; Lee JH; Hong SI; Lee KH; Choe TB; Park IC
J Thorac Oncol; 2011 Aug; 6(8):1313-9. PubMed ID: 21642861
[TBL] [Abstract][Full Text] [Related]
14. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells.
Edwards A; Li J; Atadja P; Bhalla K; Haura EB
Mol Cancer Ther; 2007 Sep; 6(9):2515-24. PubMed ID: 17876048
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.
Del Bufalo D; Desideri M; De Luca T; Di Martile M; Gabellini C; Monica V; Busso S; Eramo A; De Maria R; Milella M; Trisciuoglio D
Mol Cancer; 2014 Oct; 13():230. PubMed ID: 25301686
[TBL] [Abstract][Full Text] [Related]
16. The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.
Dai Y; Chen S; Kmieciak M; Zhou L; Lin H; Pei XY; Grant S
Mol Cancer Ther; 2013 Jun; 12(6):878-89. PubMed ID: 23536721
[TBL] [Abstract][Full Text] [Related]
17. Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma.
Hanmod SS; Wang G; Edwards H; Buck SA; Ge Y; Taub JW; Wang Z
Pediatr Blood Cancer; 2015 Jan; 62(1):52-9. PubMed ID: 25308916
[TBL] [Abstract][Full Text] [Related]
18. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
[TBL] [Abstract][Full Text] [Related]
19. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
Vallo S; Mani J; Stastny M; Makarević J; Juengel E; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
Invest New Drugs; 2013 Apr; 31(2):265-72. PubMed ID: 22801803
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.
Wang G; Niu X; Zhang W; Caldwell JT; Edwards H; Chen W; Taub JW; Zhao L; Ge Y
Cancer Lett; 2015 Jan; 356(2 Pt B):656-68. PubMed ID: 25458954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]